Irina Panarina

Biography

Russia is one of the key markets for AstraZeneca. In October 2015, in the territory of the Kaluga region, the grand opening of the company's plant in Russia took place. The total investment in the establishment of the company amounted to 224 million US dollars. In addition, AstraZeneca is one of the largest companies investing in scientific and research activities. In Russia, we conduct clinical trials, which now include more than six thousand patients. We are also working to strengthen the evidence base, and seven and a half thousand patients are participating in our studies of real clinical practice. In addition, in 2016 we expanded our scientific cooperation with the Russian Society of Clinical Oncology and continued our partnership with the biomedical cluster Skolkovo. We work closely with the medical community to provide Russian patients with innovative drugs for the treatment of socially significant diseases. It is important for us to contribute to the improvement of knowledge sharing in the Russian medical community, informing health professionals about the latest scientific developments. We are confident that the involvement of Russian scientists in international research projects will be the key to the innovative development of Russian science and will bring our experience in the field of scientific research and development accumulated throughout the world to Russia. 

Research Interest

biopharmaceutics